Company intelligence / Profile preview

Healx

Cambridge, England, United Kingdom

Ownership: Private
Employees: ~75
Development stage: Phase 2

Overview

Healx’s AI-driven approach has led to FDA clearance of an IND for HLX‑1502 in neurofibromatosis type 1, now entering Phase 2 clinical trials. The company uses its proprietary AI platform to accelerate drug discovery for rare diseases by analyzing millions of data points to find new treatment opportunities using known compounds[4][5]. No published results from completed clinical trials as of May 2025.

Therapeutic areas: Rare Diseases
Modalities: small molecules
Industry: Biotech

Drug pipeline

7 assets

gaboxadol

6 more assets in the full pipeline.

Request access →

Partnerships

Not specifically listed in available sources.

Beyond the preview

Go deeper on Healx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Healx.

Explore the full profile